Blood coagulation factor VIIa contains sodium, magnesium and calcium sites. In the present study, sodium increased the amidolytic activity of factor VIIa by ∼20-fold and stabilized the sodium loops and the tissue factor-binding region; however, rubidium occupied two calcium sites in factor VIIa but not the sodium site.
Keywords: blood coagulation factor VIIa, rubidium, calcium, magnesium, sodium
Abstract
Coagulation factor VIIa (FVIIa) consists of a γ-carboxyglutamic acid (GLA) domain, two epidermal growth factor-like (EGF) domains and a protease domain. FVIIa binds three Mg2+ ions and four Ca2+ ions in the GLA domain, one Ca2+ ion in the EGF1 domain and one Ca2+ ion in the protease domain. Further, FVIIa contains an Na+ site in the protease domain. Since Na+ and water share the same number of electrons, Na+ sites in proteins are difficult to distinguish from waters in X-ray structures. Here, to verify the Na+ site in FVIIa, the structure of the FVIIa–soluble tissue factor (TF) complex was solved at 1.8 Å resolution containing Mg2+, Ca2+ and Rb+ ions. In this structure, Rb+ replaced two Ca2+ sites in the GLA domain and occupied three non-metal sites in the protease domain. However, Rb+ was not detected at the expected Na+ site. In kinetic experiments, Na+ increased the amidolytic activity of FVIIa towards the synthetic substrate S-2288 (H-d-Ile-Pro-Arg-p-nitroanilide) by ∼20-fold; however, in the presence of Ca2+, Na+ had a negligible effect. Ca2+ increased the hydrolytic activity of FVIIa towards S-2288 by ∼60-fold in the absence of Na+ and by ∼82-fold in the presence of Na+. In molecular-dynamics simulations, Na+ stabilized the two Na+-binding loops (the 184-loop and 220-loop) and the TF-binding region spanning residues 163–180. Ca2+ stabilized the Ca2+-binding loop (the 70-loop) and Na+-binding loops but not the TF-binding region. Na+ and Ca2+ together stabilized both the Na+-binding and Ca2+-binding loops and the TF-binding region. Previously, Rb+ has been used to define the Na+ site in thrombin; however, it was unsuccessful in detecting the Na+ site in FVIIa. A conceivable explanation for this observation is provided.
1. Introduction
Human factor VII (FVII) is a vitamin K-dependent plasma protein that is synthesized by hepatocytes and secreted into the blood as a single-chain molecule with a molecular weight of ∼50 000 (Broze & Majerus, 1980 ▸; Bajaj et al., 1981 ▸). FVII consists of an N-terminal γ-carboxyglutamic acid (GLA) domain, a short hydrophobic segment, two epidermal growth factor-like (EGF) domains and a C-terminal serine protease module, which consists of two β-barrel subdomains (Davie et al., 1991 ▸). Several coagulation enzymes, including FXa, FIXa and FVIIa, activate FVII (Radcliffe & Nemerson, 1976 ▸; Bajaj et al., 1981 ▸; Masys et al., 1982 ▸; Davie et al., 1991 ▸; Yamamoto et al., 1992 ▸; Neuenschwander et al., 1993 ▸; Butenas & Mann, 1996 ▸). In each case, activation of FVII involves the cleavage of a single peptide bond between Arg152 and Ile153 located in the connecting region between the EGF2 and protease domains. This cleavage results in the formation of a two-chain FVIIa that consists of an N-terminal 152-residue light chain and a C-terminal 254-residue heavy chain (serine protease domain) held together by a single disulfide bond. Upon binding to tissue factor (TF), a transmembrane protein, FVIIa activates FIX to FIXa and FX to FXa during extrinsic coagulation (Davie et al., 1991 ▸). Similar to full-length TF, soluble TF (sTF) binds to FVIIa with high affinity and potentiates its enzymatic activity (Ruf et al., 1991 ▸; Waxman et al., 1992 ▸; Neuenschwander & Morrissey, 1992 ▸).
Crystal structures of the FVIIa–sTF complex revealed that FVIIa has multiple metal-binding sites. In the absence of Mg2+ the GLA domain contains seven Ca2+-binding sites (Banner et al., 1996 ▸), and in the presence of Mg2+ three specific Ca2+ sites are replaced by Mg2+ (Bajaj et al., 2006 ▸; Vadivel et al., 2013 ▸). The EGF1 domain and the protease domain each contain one Ca2+-binding site (Banner et al., 1996 ▸; Bajaj et al., 2006 ▸). In addition to a Ca2+-binding site, the protease domain also contains an Na+-binding site (Bajaj et al., 2006 ▸). Sequence similarity (Dang & Di Cera, 1996 ▸) predicts that the Na+-binding site in FVIIa is similar to those in FXa (Zhang & Tulinsky, 1997 ▸), activated protein C (APC; Schmidt et al., 2002 ▸) and FIXa (Vadivel et al., 2019 ▸) but not to that in thrombin (Di Cera et al., 1995 ▸; Zhang & Tulinsky, 1997 ▸).
In this report, we solved the structure of the FVIIa–sTF complex in the presence of Ca2+, Mg2+ and Rb+ to examine whether Rb+ can be used to identify the Na+ site in FVIIa. We performed hydrolysis of the synthetic substrate S-2288 (H-d-Ile-Pro-Arg-p-nitroanilide) in the presence and absence of Na+ and Ca2+ to investigate the kinetic effects of these metals on the activity of FVIIa. Further, we performed molecular-dynamics (MD) simulations to investigate the role of Na+ and Ca2+ in inducing structural stability in the protease domain of FVIIa.
2. Materials and methods
2.1. Expression and purification
Human FVII was expressed using the pMon3360b expression vector in BHK/VP16 cells, as described by Hippenmeyer & Highkin (1993 ▸) and Zhong et al. (2002 ▸). FVII was purified using a Ca2+-dependent monoclonal antibody and FPLC Mono Q column chromatography (Zhong et al., 2002 ▸). Purified FVII contained nine GLA residues per molecule, as measured by the procedure of Price et al. (1976 ▸), and appeared to be homogeneous on both reduced and nonreduced SDS–PAGE, with a molecular weight of ∼57 000. FVIIa was obtained using FXa-Sepharose as described previously, and the resin was removed by gentle centrifugation (Bajaj et al., 1981 ▸; Zhong et al., 2002 ▸). The purified protein was concentrated to ∼20 mg ml−1 and stored at −80°C until use. sTF (residues 1–219) was obtained from Tom Girard (Washington University, St Louis, Missouri, USA). sTF was concentrated to ∼10 mg ml−1 and stored at −80°C. Both proteins were ∼98% pure as judged by SDS–gel electrophoresis (Laemmli, 1970 ▸).
2.2. Crystallization and data collection
The benzamidine–FVIIa–sTF complex was crystallized using the hanging-drop vapour-diffusion method. Specifically, the protein drop consisted of 4 mg ml−1 FVIIa–sTF complex, 20 mM Tris–HCl pH 7.5, 200 mM RbCl, 10 mM CaCl2, 10 mM benzamidine, whereas the reservoir solution consisted of 16–22% PEG 4000, 100 mM MgCl2, 20 mM bis-Tris pH 6.5. Drops were prepared by mixing 2 µl protein solution with 2 µl reservoir solution at 20°C. Crystals appeared within seven days and were allowed to grow for 14–20 days before being flash-cooled without additional cryoprotectant. Diffraction data were collected to 1.8 Å resolution at a wavelength near the Rb absorption K edge on beamline 5.0.2 at the Advanced Light Source (ALS), Lawrence Berkeley National Laboratory.
2.3. Structure determination
Data indexing, integration and scaling were performed using the HKL-2000 suite (Otwinowski & Minor, 1997 ▸) and the crystal structure was solved by molecular replacement with AMoRe (Navaza, 1994 ▸) using the structure of the FVIIa–sTF complex (PDB entry 3th2; Vadivel et al., 2013 ▸) as the starting model. Model building was performed using Coot (Emsley et al., 2010 ▸) and refinement and validation were performed with the CCP4 suite (Collaborative Computational Project, Number 4, 1994 ▸; Winn et al., 2011 ▸; Murshudov et al., 2011 ▸). The Rb+ sites were identified by calculating the anomalous difference Fourier map using the CCP4 suite and the Ca2+ sites were identified by analyzing the Fourier difference maps. Data-processing and refinement statistics are given in Table 1 ▸. The coordinates and structure factors have been deposited in the Protein Data Bank (Berman et al., 2000 ▸) as PDB entry 4ibl.
Table 1. Data-collection and refinement statistics.
Values in parentheses are for the outer shell.
PDB code | 4ibl |
Data collection | |
Beamline | ALS beamline 5.0.2 |
Wavelength (Å) | 0.8153 |
Resolution (Å) | 68.24–1.80 |
Molecules per asymmetric unit | 1 |
Measured reflections | 654882 |
Unique reflections | 128119 |
Completeness (%) | 99.8 (100.0) |
Multiplicity | 5.1 |
R merge | 0.075 (0.566) |
Average I/σ(I) | 16.6 (2.9) |
Space group | P212121 |
a, b, c (Å) | 69.90, 81.06, 126.42 |
Refinement statistics | |
Resolution (Å) | 1.80 |
No. of non-H atoms | |
Protein | 4691 |
Ion | 17 |
Ligand | 30 |
Water | 529 |
R | 0.176 |
R free | 0.215 |
R.m.s.d.s from ideal values | |
Bond lengths (Å) | 0.024 |
Bond angles (°) | 1.972 |
Average B factor (Å2) | 23 |
Ramachandran plot | |
Most favoured regions (%) | 88.7 |
Additional allowed regions (%) | 11.1 |
Generously allowed regions (%) | 0.0 |
Disallowed regions (%) | 0.2 |
2.4. Measurement of the S-2288 amidolytic activity of FVIIa
The concentration of FVIIa used was between 0.1 and 5 µM. The concentration of S-2288 (DiaPharma) ranged from 50 µM to 20 mM. The buffer used was 50 mM Tris–HCl pH 7.4 containing 0.1% PEG and various salt combinations as given in the legends to the appropriate figures. Choline (Ch+), a larger monovalent cation, was used to keep the ionic strength constant at 0.2 M. p-Nitroanilide (pNA) release was measured continuously (ΔA 405 nm min−1) for up to 30 min using a SpectraMax 190 plate reader from Molecular Devices. An extinction coefficient of 9.9 mM −1 cm−1 at 405 nM was used to calculate the amount of pNA released (Lottenberg & Jackson, 1983 ▸). The data were processed using nonlinear least-squares regression analysis with the Marquardt algorithm (Bevington & Robinson, 1992 ▸) and the quality of the fit was evaluated using the described criterion (Straume & Johnson, 1992 ▸). The fitted parameters are given ±95% confidence limits. Initial velocity measurements of S-2288 hydrolysis were analyzed using the Henri–Michaelis–Menten equation (Segal, 1975 ▸) to yield K m and V max values.
2.5. Global analysis of initial velocity data
The equilibrium dissociation constants for the binding of the synthetic substrate S-2288 (K E,S), Na+ (K E,N) and Ca2+ (K E,C) to free FVIIa, for the binding of Na+ to substrate-bound (KES,N) or Ca2+-bound (K EC,N) FVIIa, for the binding of Ca2+ to substrate-bound (K ES,C) or Na+-bound (K EN,C) FVIIa, for the binding of substrate to Na+-bound (K EN,S) or Ca2+-bound (K EC,S) FVIIa, for the binding of Na+ to substrate- and Ca2+-bound FVIIa (K ECS,N), for the binding of Ca2+ to substrate- and Na+-bound FVIIa (K ENS,C) and for the binding of substrate to Na+- and Ca2+-bound FVIIa (K ENC,S) were calculated from initial velocity measurements of S-2288 hydrolysis according to the system of common differential equations described in Fig. 1 ▸ and using the rapid equilibrium assumption. The entire data set was globally fitted using DynaFit (Kuzmič, 2009 ▸) to extract all of the above equilibrium dissociation constants as well as the k catE, k catEN, k catEC and k catENC values. Here, N stands for Na+, C for Ca2+, S for substrate, P for product and E for the FVIIa enzyme.
Figure 1.
Equations and parameters for S-2288 hydrolysis.
2.6. Determination of K dpAB for p-aminobenzamidine (pAB) binding to FVIIa
The K dpAB for pAB binding to FVIIa was determined by its ability to competitively inhibit S-2288 hydrolysis in the absence and presence of Na+ with or without Ca2+. Each reaction mixture contained 0.1–5 µM FVIIa and 1 mM S-2288 in 50 mM Tris–HCl pH 7.4 in four varying Na+/Ca2+ conditions: (i) 200 mM ChCl/1 mM EDTA, (ii) 200 mM NaCl/1 mM EDTA, (iii) 185 mM ChCl/5 mM CaCl2 and (iv) 185 mM NaCl/5 mM CaCl2. The IC50 (the concentration of pAB required for 50% inhibition) was determined by fitting the data to the IC50 four-parameter logistic equation of Halfman (1981 ▸),
![]() |
where y is the rate of pNA release in the presence of a given concentration of pAB represented by x, a is the maximum rate of pNA release in the absence of pAB, and s is the slope factor. Each point was weighted equally and the data were fitted to (1) using the nonlinear regression analysis program GraFit from Erithcus Software. To obtain K dpAB values for the interaction of pAB with FVIIa, we used the following equation, as described by Cheng & Prusoff (1973 ▸) and further elaborated by Craig (1993 ▸),
![]() |
where [S] is the S-2288 concentration and K m is the value obtained under the different conditions used to obtain K dpAB.
2.7. Molecular-dynamics (MD) simulations
MD simulations were performed to investigate the effect of Na+ and Ca2+ binding to the protease domain of FVIIa. MD simulations were carried out in the absence and presence of Na+ or Ca2+ or of Na+ and Ca2+ using the AMBER18 program (Case et al., 2019 ▸). The FVIIa protease domain containing residues Val16 (chymotrypsin numbering; 153 in FVIIa) to Pro257 (406 in FVIIa) was used in these studies. Since the effect of Na+ and Ca2+ binding to the protease domain is being evaluated, we used only the protease domain of FVIIa in these studies. After adding H atoms, the protein structures were solvated in a truncated octahedral TIP3P box of 12 Å and the system was neutralized with chloride ions. Periodic boundary conditions, particle mesh Ewald summation and SHAKE-enabled 2 fs time steps were used in all MD simulations. Langevin dynamics temperature control was employed with a collision rate equal to 1.0 ps−1. A cutoff of 13 Å was used for nonbonding interactions. The divalent and monovalent metal-ion parameters used were taken from Li & Merz (2014 ▸) and Li et al. (2015 ▸) and the metal interactions were treated using the 12–6–4 Lennard–Jones nonbonded model. The initial configurations were subjected to a 1000-step minimization with harmonic constraints of 10 kcal mol−1 Å−2 on the protein heavy atoms. The systems were gradually heated from 0 to 300 K over a period of 50 ps with harmonic constraints. The simulations at 300 K were then continued for 50 ps, during which the harmonic constraints were gradually lifted. The systems were then equilibrated for a period of 500 ps before the 50 ns production runs. All simulations were carried out in the NPT ensemble. Equilibration and production run simulations were carried out using the Sander and PMEMD modules (optimized for CUDA) of AMBER18.0 (ff14SB), respectively (Le Grand et al., 2013 ▸; Case et al., 2019 ▸). The initial structures of the production runs were used as reference structures for calculation of the root-mean-square deviations (r.m.s.d.s) and root-mean-square fluctuations (r.m.s.f.s). All analyses were performed using the cpptraj module of AmberTools18 (Case et al., 2019 ▸).
3. Results
3.1. Structure of FVIIa–sTF
The FVIIa–sTF complex was crystallized in the presence of Ca2+, Mg2+ and Rb+ and the data were collected near the Rb K absorption edge. The FVIIa–sTF structure was determined by molecular replacement and the structure is similar to previous FVIIa–sTF complex structures. Based upon the Rb anomalous signal, three Rb+ ions were found in the GLA domain and three in the protease domain (Fig. 2 ▸). The refined occupancies for the Rb+ ions were 0.65 (Rb1), 0.65 (Rb2), 0.75 (Rb3), 0.55 (Rb4), 0.48 (Rb5) and 0.50 (Rb6), and the B factors were 48, 55, 32, 46, 52 and 46 Å2, respectively. Two of the three Rb+ ions in the GLA domain occupied the Ca2+-binding sites at positions 3 and 5 (the metal-binding site numbering in the GLA domain is based on Soriano-Garcia et al., 1992 ▸) and the third site was found on the surface. The coordination geometry of the identified Rb+ ions in FVIIa are shown in Fig. 3 ▸. Moreover, although three Rb+ ions were identified in the protease domain, none of them was found at the putative Na+ site and each is surface-bound.
Figure 2.
Structure of the FVIIa–sTF complex. Cartoon representation of the FVIIa–sTF structure obtained with Ca2+, Mg2+ and Rb+. The FVIIa light chain is in blue and the heavy chain is in red. sTF is shown in magenta. The active-site residue Ser195 is shown in space-filling representation and benzamidine (Bz) bound at the active site is shown in stick representation. The Ca2+, Mg2+ and Rb+ ions bound to FVIIa are shown as green, orange and purple spheres, respectively. Note that the Ca2+ ions at positions 3 and 5 are replaced by Rb1 and Rb2, respectively.
Figure 3.
Coordination geometries of Rb+ sites in the FVIIa–sTF structure. The residues coordinated to Rb+ are shown in stick representation. The electron-density (2F obs − F calc) maps (black) are contoured at 1σ and the anomalous maps (in blue) for Rb+ are contoured at 3σ. C atoms are green, N atoms are blue and O atoms are red. The C atoms are coloured grey in the residue coordinated to Rb+ from the symmetry-related molecule. The Rb+ ions and water molecules are shown as purple and red spheres, respectively. The residues coordinated to Rb4, Rb5 and Rb6 are in the protease domain and are labelled with chymotrypsin numbering.
3.2. Effects of monovalent cations on the amidolytic activity of FVIIa
Our initial efforts were directed towards finding an inert monovalent cation that could be used to keep the ionic strength constant during the kinetic experiments. Hydrolysis of S-2288 by FVIIa was measured at various concentrations of Rb+, Cs+ or choline (Ch+) as inert monovalent cations. Rb+, Cs+ or Ch+ did not inhibit or potentiate the amidolytic activity of FVIIa (Fig. 4 ▸ a). Further, Na+ potentiated the amidolytic activity of FVIIa to a similar extent whether or not Ch+ was present (Fig. 4 ▸ b). Thus, Ch+ was used as the compensatory ion in subsequent experiments.
Figure 4.
Effect of monovalent cations on the amidolytic activity of FVIIa. (a) Effect of Rb+, Cs+ or Ch+ on the amidolytic activity of FVIIa. Reaction mixtures consisted of 1 mM S-2288 and 1 µM FVIIa in 50 mM Tris pH 7.4, 0.1% PEG 8000, 1 mM EDTA and various concentrations of either Rb+ (closed circles), Cs+ (open triangles) or Ch+ (open circles). The chloride salt of each ion was used. (b) Effect of Na+ on the amidolytic activity of FVIIa. The buffer conditions are the same as in (a). Open circles represent an experiment where increasing concentrations of Na+ were used in the absence of a compensating monovalent ion. Closed circles represent an experiment where the monovalent cation concentration was kept constant at 0.2 M by the addition of Ch+ as a compensating ion.
3.3. Effect of Na+ and Ca2+ on the potentiation of S-2288 hydrolysis by FVIIa
The enhancement of substrate-hydrolysis activity by various concentrations of Na+ or Ca2+ at varying concentrations of S-2288 is shown in Figs. 5 ▸(a) and 5 ▸(b), respectively. Similarly, the enhancement of substrate-hydrolysis activity at varying concentrations of Ca2+ in the presence of constant Na+ (200 mM) or at varying concentrations of Na+ in the presence of constant Ca2+ (5 mM) is depicted in Figs. 5 ▸(c) and 5 ▸(d), respectively. The entire data set was globally fitted using DynaFit according to Fig. 1 ▸, and the calculated parameters are given in Table 2 ▸. The binding of Na+ to FVIIa had no effect on the S-2288 substrate affinity; however, it increased the k cat ∼21.4-fold. Conversely, the binding of Ca2+ to FVIIa decreased the affinity of the substrate by ∼3.7-fold but increased the k cat by ∼231-fold. Na+ binding to Ca2+-bound FVIIa had little effect on the substrate affinity or the k cat (Tables 2 ▸ and 3 ▸). Further, Ca2+ binding to Na+-bound FVIIa decreased the affinity of the substrate by ∼3.3-fold and increased the k cat by ∼12.4-fold. Cumulatively, these data suggest that Na+ has relatively little effect on the affinity of FVIIa for substrate but considerably increases the k cat in the absence of Ca2+. However, Na+ has essentially no effect on the substrate affinity or k cat in the presence of Ca2+. In contrast, Ca2+ decreases the affinity of FVIIa for substrate and substantially increases the k cat in the absence or presence of Na+ (Tables 2 ▸ and 3 ▸). The conclusions from the global fitting approach were independently verified by initial velocity studies of peptidyl substrate cleavage at near-saturating concentrations of Ca2+ and/or Na+. There was good agreement between the steady-state kinetic constants determined under these conditions (Table 3 ▸) and those inferred from the global analysis (Table 2 ▸).
Figure 5.
Na+- and Ca2+-mediated potentiation of S-2288 hydrolysis by FVIIa. (a) Na+-mediated potentiation of S-2288 hydrolysis by FVIIa in the absence of Ca2+. Monovalent ion concentrations are 0 mM Na+/200 mM Ch+ (closed circles), 10 mM Na+/190 mM Ch+ (open circles), 25 mM Na+/175 mM Ch+ (closed squares), 50 mM Na+/150 mM Ch+ (open squares), 75 mM Na+/125 mM Ch+ (closed triangles), 100 mM Na+/100 mM Ch+ (open triangles), 125 mM Na+/75 mM Ch+ (closed hexagons), 150 mM Na+/50 mM Ch+ (open hexagons), 165 mM Na+/35 mM Ch+ (closed inverted triangles), 175 mM Na+/25 mM Ch+ (open inverted triangles), 190 mM Na+/10 mM Ch+ (closed diamonds) and 200 mM Na+/0 mM Ch+ (open diamonds). The concentration of FVIIa used was from 0.1 to 5 µM; for consistency, the data were normalized to 1 µM enzyme concentration. (b) Ca2+-mediated potentiation of S-2288 hydrolysis by FVIIa in the absence of Na+. Ca2+ concentrations are 0 mM (closed circles), 25 µM (open circles), 50 µM (closed squares), 0.10 mM (open squares), 0.25 mM (closed triangles), 0.50 mM (open triangles), 1.0 mM (closed hexagons), 3.0 mM (open hexagons) and 5.0 mM (closed inverted triangles). The ionic strength was kept constant in each reaction mixture by adding 185–200 mM Ch+. The FVIIa concentrations used were 0.1–5 µM. As in (a), the data were normalized to 1 µM FVIIa concentration. (c) Ca2+-mediated potentiation of S-2288 hydrolysis by FVIIa in the presence of Na+. Ca2+ concentrations are 0 mM (closed circles), 25 µM (open circles), 50 µM (closed squares), 0.10 mM (open squares), 0.25 mM (closed triangles), 0.50 mM (open triangles), 1 mM (closed hexagons), 2.0 mM (open hexagons), 3.0 mM (closed inverted triangles) and 5.0 mM (open inverted triangles). The concentration of Na+ in each case was 185 mM, and the Ch+ concentration was varied to keep the ionic strength constant. The FVIIa concentrations used were 0.1–5 µM and were normalized to 1 µM as in (a) and (b). (d) Na+-mediated potentiation of S-2288 hydrolysis by FVIIa in the presence of Ca2+. Na+ concentrations are 0 mM (closed circles), 25 mM (open circles), 50 mM (closed squares), 75 mM (open squares), 100 mM (closed triangles), 125 mM (open triangles), 150 mM (closed diamonds) and 185 mM (closed hexagons). Each reaction mixture contained 5 mM Ca2+ and an appropriate concentration of Ch+ to maintain a constant ionic strength. The concentration of FVIIa used was 0.1 µM, which was normalized to 1 µM as in (a) and (b). All lines are drawn following global analysis according to Fig. 1 ▸ using the fitted values in Table 2 ▸.
Table 2. Parameters for Fig. 1 ▸ determined by global fit analysis.
Note that the value of K ENC,S is the same as that of K ECN,S and that the value of k catECN is the same as that of k catENC.
Parameter | Fitted value |
---|---|
K E,S (mM) | 1.9 ± 0.3 |
K EN,S (mM) | 2.4 ± 0.4 |
K EC,S (mM) | 9.4 ± 0.7 |
K ENC,S (mM) | 8.2 ± 0.9 |
K E,N (mM) | 160 ± 30 |
K ES,N (mM) | 155 ± 32† |
K EC,N (mM) | 168 ± 41‡ |
K ECS,N (mM) | 149 ± 35§ |
K E,C (mM) | 0.20 ± 0.05 |
K ES,C (mM) | 0.81 ± 0.20¶ |
K EN,C (mM) | 0.52 ± 0.16 |
K ENS,C (mM) | 1.87 ± 0.43†† |
k catE (min−1) | 0.8 ± 0.2 |
k catEN (min−1) | 21.9 ± 1.8 |
k catEC (min−1) | 215.2 ± 24.1 |
k catENC (min−1) | 257.1 ± 32.5 |
K ES,N was obtained using K E,N(K EN,S/K E,S)
K EC,N was obtained using K E,N(K EN,C/K E,C).
K ECS,N was obtained using K ES,N(K ENS,C/K ES,C).
K ES,C was obtained using K E,C(K EC,S/K E,S).
K ENS,C was obtained using K EN,C(K ENC,S/K EN,S).
Table 3. Effect of Na+ and Ca2+ on the hydrolysis of S-2288 by FVIIa.
To keep the ionic strength constant, Ch+ was used at 200 mM in the absence of Na+ and Ca2+. The concentration of Na+ was 200 mM in the absence of Ca2+ and 185 mM in the presence of 5 mM Ca2+. The buffer used was 50 mM Tris pH 7.4 containing 0.1% PEG 8000. The results presented are the average of three experiments ± SE.
Conditions | ||||
---|---|---|---|---|
Na+ | Ca2+ | K m (mM) | k cat (min−1) | k cat/K m † (min−1 mM −1) |
— | — | 2.4 ± 0.4 | 0.9 ± 0.1 | 0.4 (1)† |
+ | — | 2.2 ± 0.3 | 19.3 ± 0.9 | 8.8 (22) |
— | + | 8.8 ± 1.3 | 207.7 ± 15 | 23.6 (59) |
+ | + | 7.8 ± 0.7 | 239.9 ± 10 | 32.8 (82) |
The fold change in the specificity constant k cat/K m is given in parentheses.
3.4. Molecular-dynamics studies
To investigate the role of Na+ in FVIIa, we performed MD simulations on the FVIIa protease domain for 50 ns each in the presence of Na+, Ca2+ or of Na+ and Ca2+ as well as in the absence of these metals using the AMBER18 package (Case et al., 2019 ▸). The r.m.s.d. and the average r.m.s.f. for the backbone atoms of the FVIIa protease domain for the 50 ns MD data are presented in Fig. 6 ▸. The MD data indicate that the presence of Na+, Ca2+ or of Na+ and Ca2+ stabilizes the FVIIa protease domain compared with the metal-free form (Fig. 6 ▸ a). The average r.m.s.f. for the backbone atoms of each residue presented in Fig. 6 ▸(b) indicate that Na+ reduces residue fluctuations (∼0.75 Å) in the two Na+-binding loops (184-loop, residues 183–194; 220-loop, residues 216–225) as well as in the tissue factor-binding region (residues 163–180), while Ca2+ reduces fluctuations (∼0.5 Å) in the Ca2+-binding loop residues (residues 70–80) as well as in the Na+-binding loops. The presence of both Ca2+ and Na+ reduces fluctuations in the Ca2+-binding loop (∼0.6 Å) and the two Na+-binding loops (∼0.75 Å; residues 183–194 and residues 216–225) as well as the tissue factor-binding region (∼1.0 Å; residues 163–180). Cumulatively, the MD data suggest that Na+ plays a role in stabilizing the two Na+-binding loops and the tissue factor-binding region in the FVIIa protease domain.
Figure 6.
The r.m.s.d. and the average r.m.s.f. of the backbone atoms of the FVIIa protease domain in the absence as well as the presence of Na+, of Ca2+ or of Na+ and Ca2+. (a) R.m.s.d. of backbone atoms of FVIIa over 50 ns MD trajectories. (b) Comparative r.m.s.f. plots of the backbone atoms of FVIIa during 50 ns MD simulations. In both (a) and (b) black represents the absence of Na+ and Ca2+, green represents the presence of Na+, red represents the presence of Ca2+ and blue represents the presence of both Na+ and Ca2+. Arrows in (b) indicate the reduced fluctuations in the residues of the Ca2+ and Na+ loops in the presence of Na+ or Ca2+ as well as of both Na+ and Ca2+.
4. Discussion and conclusion
Dang & Di Cera (1996 ▸) compared the sequences of serine proteases and classified them into two classes: proteases with Pro225 that lack the Na+ site and proteases with Tyr225 or Phe225 that possess the Na+ site. As per the Dang and Di Cera classification, the coagulation proteases thrombin, FVIIa, FIXa and FXa, as well as APC and complement C1r and C1s, which carry Tyr225 or Phe225, bind Na+, while trypsin, chymotrypsin, elastase, FXIa, FXIIa, kallikrein, urokinase and plasmin, which carry Pro225, do not bind Na+. Accordingly, synthetic substrate hydrolysis by thrombin, FIXa, FXa and APC is allosterically enhanced by Na+ binding (Orthner & Kosow, 1978 ▸, 1980 ▸; Steiner & Castellino, 1985 ▸; Dang et al., 1995 ▸; Dang & Di Cera, 1996 ▸; He & Rezaie, 1999 ▸; Rezaie & He, 2000 ▸; Underwood et al., 2000 ▸; Schmidt et al., 2002 ▸, 2005 ▸). Further, the residue 225 specificity of Na+ binding in thrombin (Dang & Di Cera, 1996 ▸) and FIXa (Schmidt et al., 2005 ▸) has been demonstrated by mutating Tyr225 to Pro: enhancement of synthetic substrate hydrolysis by Na+ was impaired by a Tyr225Pro mutation in both enzymes.
Identification of the metal-binding sites in proteins is important in order to understand their functions in biology. The extensive work of Marjorie Harding on metal-binding sites in proteins provides a framework to define and identify metal ions in protein structures (Harding, 1999 ▸, 2000 ▸, 2002 ▸, 2004 ▸, 2006 ▸; Harding et al., 2010 ▸). Her analysis of the metal–ligand interactions in protein structures and comparisons with the Cambridge Structural Database (CSD; Groom et al., 2016 ▸) for ligands that are analogues of amino-acid side chains in proteins provide guidelines for metal–donor atom distances, coordination numbers and the extent of distortion from the ideal geometry. Harding’s analyses further define the architecture of metal-coordination groups in proteins and their preferences for Na, Mg, K, Ca, Mn, Fe, Co, Ni, Cu and Zn metal cations. Among these cations, the interactions between Na+ and ligand atoms from the protein or water molecules are more electrostatic and to some extent less covalent in nature; thus, it is difficult to precisely define the interaction distances for Na+ (Harding, 2006 ▸). Although the ideal coordination distance for Na+ is 2.38 ± 0.10 Å, this is not always the case in protein structures. In many instances, the distances are longer and there are fewer than six coordinate ligand atoms (Harding, 2002 ▸), which necessitates additional documentation to unequivocally define Na+ sites in proteins.
Furthermore, the crystallographic identification of Na+ in proteins is not straightforward due to the comparable electron density of a water molecule and the Na+ ion (Stubbs & Bode, 1993 ▸). In this context, enhancement of thrombin activity by Na+ was observed in 1980 (Orthner & Kosow, 1980 ▸); however, the Na+ site was not crystallographically defined until 1995 (Di Cera et al., 1995 ▸). It was the work of Di Cera et al. (1995 ▸) and Zhang & Tulinsky (1997 ▸) that identified the Na+ site by soaking thrombin crystals with Rb+. The Rb+–thrombin structure revealed the location of the Na+ ion and its coordination to the main-chain carbonyl O atoms of residues 221A and 224 and four water molecules. This is represented schematically in Fig. 7 ▸(a). Based on the location of the Na+ site in thrombin, Zhang & Tulinsky (1997 ▸) re-examined the structure of FXa (Padmanabhan et al., 1993 ▸), found a water molecule coordinated to four carbonyl O atoms and correctly replaced it with Na+. The Na+ ion at this site in FXa is coordinated to the main-chain carbonyl O atoms of residues 184A, 185, 221A and 224 and two water molecules (Zhang & Tulinsky, 1997 ▸). Later, Schmidt et al. (2002 ▸), Bajaj et al. (2006 ▸) and Vadivel et al. (2019 ▸) reported that Na+ at a similar site in APC, FVIIa and FIXa, respectively, is coordinated to four carbonyl O atoms (Fig. 7 ▸ b) and two water molecules. A four-residue insertion in the 184-loop of thrombin prevents the participation of the 184-loop in Na+ binding (Fig. 7 ▸ a).
Figure 7.
Comparison of the Na+-binding site between thrombin and FVIIa, FIXa, FXa and APC. (a) The Na+-binding site of thrombin. Two of the main-chain carbonyl O atoms (Arg221A and Lys224) of the 220-loop and four water molecules, which serve as ligands for Na+, are shown. Only the backbone atoms, without the carbonyl O atoms, except for those that serve as ligands for the Na+ ion, are shown in stick representation. The Na+ ions (yellow) and water molecules (red) are shown as spheres. (b) The Na+-binding sites in FVIIa (green), FIXa (blue), FXa (orange) and APC (wheat). The main-chain carbonyl O atoms from both the 184-loop (184A and 185) and the 220-loop (221A and 224) residues serve as ligands for Na+. As in (a), only the backbone atoms, without the carbonyl O atoms, except for those that serve as ligands for Na+, are shown in stick representation. The Na+ ion is shown as a green sphere for FVIIa, a blue sphere for FIXa, an orange sphere for FXa and a wheat sphere for APC. For clarity, the two water molecules that also coordinate to Na+ in these proteases are not shown.
As found for FIXa (Dang & Di Cera, 1996 ▸; Schmidt et al., 2005 ▸; Gopalakrishna & Rezaie, 2006 ▸), Na+ enhances synthetic substrate hydrolysis by FVIIa in the absence of Ca2+ and has essentially no effect in the presence of Ca2+ (Fig. 5 ▸; Petrovan & Ruf, 2000 ▸). In contrast, Na+ enhances synthetic substrate hydrolysis by FXa (Orthner & Kosow, 1978 ▸; Rezaie & He, 2000 ▸; Underwood et al., 2000 ▸) and APC (Steiner & Castellino, 1985 ▸; He & Rezaie, 1999 ▸; Schmidt et al., 2002 ▸) in the absence or presence of Ca2+. Further, in Ca2+-containing buffers, Na+ had a minimal effect on the interaction of FXa with FVa (Camire, 2002 ▸), of FIXa with FVIIIa (Schmidt et al., 2005 ▸) and of FVIIa with TF (Petrovan & Ruf, 2000 ▸; Bajaj et al., 2006 ▸). Na+ also had a minimal effect on the activation of prothrombin by FXa/FVa (Camire, 2002 ▸), of FX by FIXa/FVIIIa (Schmidt et al., 2005 ▸; Gopalakrishna & Rezaie, 2006 ▸) and of FX by FVIIa/TF (Petrovan & Ruf, 2000 ▸; Gopalakrishna & Rezaie, 2006 ▸). Whether or not Na+ plays a role in the inactivation of FVa or FVIIIa by APC/protein S has not been investigated. Thus, it would appear that the respective cofactor in the cases of FVIIa, FIXa or FXa eliminates the need for Na+ for optimal biological activity. Further work is required to establish the role of Na+ in the inactivation of FVa or FVIIIa by APC/protein S.
In the MD simulations, compared with free FVIIa, Na+ stabilized the Na+-binding loops and the TF-binding region, whereas Ca2+ stabilized the Ca2+-binding loop and the Na+-binding loops but not the TF-binding region. Thus, Na+ contributes in part towards stabilization of the FVIIa protease domain. In this context, it is particularly interesting to reinvestigate crystal structures of FVIIa which were determined in the absence of TF, particularly PDB entries 1klj and 1kli, which both lack an Na+ ion at the expected Na+-binding site (Sichler et al., 2002 ▸). While the absence of an Na+ ion in PDB entry 1klj is consistent with its limited resolution of 2.44 Å, the data set for PDB entry 1kli, which was determined at 1.7 Å resolution, deserves a more careful analysis. Indeed, the relevant solvent structure is intriguing. According to the PDB entry 1kli coordinate set, a water molecule is positioned in the neighbourhood of the three carbonyls of Tyr184, Thr221 and His224. Such a three-carbonyl oxygen coordination is inconsistent with an ordered water molecule, but is consistent with a Na+ ion. Furthermore, current structure-refinement protocols, including the automatic PDB-REDO (Joosten et al., 2011 ▸, 2014 ▸), reveal significant positive difference electron density at more than 5σ above the mean. Consequently, a reanalysis with current refinement protocols strongly favours the presence of an Na+ ion in FVIIa in the absence of TF (Fig. 8 ▸).
Figure 8.
The Na+ site in the FVIIa protease domain in the absence of TF (PDB entry 1kli). The carbonyl O atoms of FVIIa residues Tyr184, Ser185, Thr221 and His224 and the two water molecules that serve as ligands for Na+ are shown. The electron-density (2F obs − F calc) map is contoured at 1σ. The Na+ ion and water molecules are shown as purple and red spheres, respectively.
Notably, structural identification of the Na+ site in thrombin was determined by soaking the crystals with Rb+ (Di Cera et al., 1995 ▸). Here, we made a similar effort to identify the Na+ site in FVIIa using Rb+ as a probe. However, unlike thrombin, Rb+ did not occupy the Na+ site in the FVIIa protease domain. A possible explanation for the absence of Rb+ occupancy at the Na+ site in FVIIa is that the exact composition of the Na+ site differs between FVIIa and thrombin. The Na+ site in thrombin is located in the prominent water channel filled with more than 20 highly conserved water molecules linked together by a hydrogen-bond network that also connects to the protein (Zhang & Tulinsky, 1997 ▸). Four water molecules in this solvent channel and two carbonyl O atoms from the 220-loop coordinate to Na+ in thrombin. Notably, the Na+ site in thrombin is deep and is exposed to the surface, which allows Rb+ to occupy the Na+ site even though Rb+ has a larger ionic radius (1.52 Å; Shannon, 1976 ▸) and requires a longer coordination distance compared with Na+ (ionic radius of 1.02 Å). The ideal coordination distance for Rb–O is 2.98 Å (it varies between 2.7 and 3.2 Å in small molecules; Groom et al., 2016 ▸) as determined using large-angle X-ray scattering and extended X-ray absorption fine structure studies (D’Angelo & Persson, 2004 ▸). Similar to in small molecules, the Rb+ coordination distance varies between 2.7 and 3.6 Å in proteins (Zhang & Tulinsky, 1997 ▸; Berman et al., 2000 ▸; Korolev et al., 2001 ▸). Comparatively, the Na+ coordination distance varies from 2.4 to 3.01 Å in proteins (Harding, 2002 ▸). Accordingly, Rb+ occupancy at the Na+ site in thrombin results in the rearrangement of water molecules as well as the involvement of the 184-loop residue Tyr184A. Compared with thrombin, the absence of a four-residue insertion in the 184-loop of FVIIa leads to four carbonyl O atoms (Tyr184, Ser185, Thr221 and His224) from the 184-loop and 220-loop and two water molecules coordinating to Na+. Consequently, the Na+ site in FVIIa is narrow and is not exposed to the surface. Thus, spatial restraints imposed by the 184-loop and 220-loop in FVIIa prevent Rb+ occupancy at the Na+ site due to its larger ionic radius compared with Na+ (Fig. 9 ▸). This is consistent with the previous finding that Rb+ does not always occupy the Na+ site in macromolecules, especially in less exposed and narrow spaces (Machius et al., 1998 ▸; Nonaka et al., 2003 ▸). Thus, the molecular environment of the Na+ site in a protein determines whether Rb+ can occupy the Na+ site. Overall, the analysis points out that the Na+ site in FVIIa is similar to those in FIXa, FXa and APC but not to that in thrombin.
Figure 9.
Comparison of the molecular environment of the Na+ site in FVIIa and thrombin. In FVIIa, residues from both the 184-loop and the 220-loop (Tyr184, Ser185, Thr221 and His224) participate in coordinating to Na+, whereas in thrombin only residues from the 220-loop (Arg221A and Lys224) are involved. The spatial restraints imposed by the 184-loop and 220-loop prevent Rb+ occupancy at the Na+ site in FVIIa. The Na+ and Rb+ ions are shown as pink and purple spheres, respectively. The ionic radii of Na+ (1.02 Å) and Rb+ (1.52 Å) were used to draw the spheres (Shannon, 1976 ▸). The residues that serve as ligands for Na+ are shown in stick representation. Residue 225, which defines the presence of a Na+ site in these proteases, is also shown in stick representation. The FVIIa loops are shown in green and the thrombin loops are in yellow. The four-residue insertion in the 184-loop of thrombin is shown in magenta.
Supplementary Material
PDB reference: factor VIIa–soluble tissue factor complex, 4ibl
Acknowledgments
We thank Dr Michael Sawaya and the UCLA–DOE X-ray Crystallization and Crystallography Core Facilities (supported by Department of Energy grant DE-FC02-02ER63421) for assistance with crystallization and data collection.
Funding Statement
This work was funded by National Heart, Lung, and Blood Institute grants R01HL141850 and P01HL139420. Austrian Science Fund grant W1213 to Hans Brandstetter.
References
- Bajaj, S. P., Rapaport, S. I. & Brown, S. F. (1981). J. Biol. Chem. 256, 253–259. [PubMed]
- Bajaj, S. P., Schmidt, A. E., Agah, S., Bajaj, M. S. & Padmanabhan, K. (2006). J. Biol. Chem. 281, 24873–24888. [DOI] [PubMed]
- Banner, D. W., D’Arcy, A., Chène, C., Winkler, F. K., Guha, A., Konigsberg, W. H., Nemerson, Y. & Kirchhofer, D. (1996). Nature, 380, 41–46. [DOI] [PubMed]
- Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N. & Bourne, P. E. (2000). Nucleic Acids Res. 28, 235–242. [DOI] [PMC free article] [PubMed]
- Bevington, P. R. & Robinson, K. D. (1992). Data Reduction and Error Analysis for the Physical Sciences. New York: McGraw–Hill.
- Broze, G. J. Jr & Majerus, P. W. (1980). J. Biol. Chem. 255, 1242–1247. [PubMed]
- Butenas, S. & Mann, K. G. (1996). Biochemistry, 35, 1904–1910. [DOI] [PubMed]
- Camire, R. M. (2002). J. Biol. Chem. 277, 37863–37870. [DOI] [PubMed]
- Case, D. A., Ben-Shalom, I. Y., Brozell, S. R., Cerutti, D. S., Cheatham, T. E. III, Cruzeiro, V. W. D., Darden, T. A., Duke, R. E., Ghoreishi, D., Gilson, M. K., Gohlke, H., Goetz, A. W., Greene, D., Harris, R., Homeyer, N., Izadi, S., Kovalenko, A., Kurtzman, T., Lee, T. S., LeGrand, S., Li, P., Lin, C., Liu, J., Luchko, T., Luo, R., Mermelstein, D. J., Merz, K. M., Miao, Y., Monard, G., Nguyen, C., Nguyen, H., Omelyan, I., Onufriev, A., Pan, F., Qi, R., Roe, D. R., Roitberg, A., Sagui, C., Schott-Verdugo, S., Shen, J., Simmerling, C. L., Smith, J., Salomon-Ferrer, R., Swails, J., Walker, R. C., Wang, J., Wei, H., Wilson, L., Wolf, R. M., Wu, X., Xiao, L., Xiong, Y., York, D. M. & Kollman, P. A. (2019). AMBER2019. University of California, San Francisco, USA.
- Cheng, Y.-C. & Prusoff, W. H. (1973). Biochem. Pharmacol. 22, 3099–3108. [DOI] [PubMed]
- Collaborative Computational Project, Number 4 (1994). Acta Cryst. D50, 760–763.
- Craig, D. A. (1993). Trends Pharmacol. Sci. 14, 89–91. [DOI] [PubMed]
- Dang, Q. D. & Di Cera, E. (1996). Proc. Natl Acad. Sci. USA, 93, 10653–10656. [DOI] [PMC free article] [PubMed]
- Dang, Q. D., Vindigni, A. & Di Cera, E. (1995). Proc. Natl Acad. Sci. USA, 92, 5977–5981. [DOI] [PMC free article] [PubMed]
- D’Angelo, P. & Persson, I. (2004). Inorg. Chem. 43, 3543–3549. [DOI] [PubMed]
- Davie, E. W., Fujikawa, K. & Kisiel, W. (1991). Biochemistry, 30, 10363–10370. [DOI] [PubMed]
- Di Cera, E., Guinto, E. R., Vindigni, A., Dang, Q. D., Ayala, Y. M., Wuyi, M. & Tulinsky, A. (1995). J. Biol. Chem. 270, 22089–22092. [DOI] [PubMed]
- Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta Cryst. D66, 486–501. [DOI] [PMC free article] [PubMed]
- Gopalakrishna, K. & Rezaie, A. R. (2006). Thromb. Haemost. 95, 936–941. [DOI] [PubMed]
- Groom, C. R., Bruno, I. J., Lightfoot, M. P. & Ward, S. C. (2016). Acta Cryst. B72, 171–179. [DOI] [PMC free article] [PubMed]
- Halfman, C. J. (1981). Methods Enzymol. 74, 481–497. [DOI] [PubMed]
- Harding, M. M. (1999). Acta Cryst. D55, 1432–1443. [DOI] [PubMed]
- Harding, M. M. (2000). Acta Cryst. D56, 857–867. [DOI] [PubMed]
- Harding, M. M. (2002). Acta Cryst. D58, 872–874. [DOI] [PubMed]
- Harding, M. M. (2004). Acta Cryst. D60, 849–859. [DOI] [PubMed]
- Harding, M. M. (2006). Acta Cryst. D62, 678–682. [DOI] [PubMed]
- Harding, M. M., Nowicki, M. W. & Walkinshaw, M. D. (2010). Crystallogr. Rev. 16, 247–302.
- He, X. & Rezaie, A. R. (1999). J. Biol. Chem. 274, 4970–4976. [DOI] [PubMed]
- Hippenmeyer, P. & Highkin, M. (1993). Nat. Biotechnol. 11, 1037–1041. [DOI] [PubMed]
- Joosten, R. P., Joosten, K., Cohen, S. X., Vriend, G. & Perrakis, A. (2011). Bioinformatics, 27, 3392–3398. [DOI] [PMC free article] [PubMed]
- Joosten, R. P., Long, F., Murshudov, G. N. & Perrakis, A. (2014). IUCrJ, 1, 213–220. [DOI] [PMC free article] [PubMed]
- Korolev, S., Dementieva, I., Sanishvili, R., Minor, W., Otwinowski, Z. & Joachimiak, A. (2001). Acta Cryst. D57, 1008–1012. [DOI] [PMC free article] [PubMed]
- Kuzmič, P. (2009). Methods Enzymol. 467, 247–280. [DOI] [PubMed]
- Laemmli, U. K. (1970). Nature, 227, 680–685. [DOI] [PubMed]
- Le Grand, S., Götz, A. W. & Walker, R. C. (2013). Comput. Phys. Commun. 184, 374–380.
- Li, P. & Merz, K. M. Jr (2014). J. Chem. Theory Comput. 10, 289–297. [DOI] [PMC free article] [PubMed]
- Li, P., Song, L. F. & Merz, K. M. Jr (2015). J. Chem. Theory Comput. 11, 1645–1657. [DOI] [PubMed]
- Lottenberg, R. & Jackson, C. M. (1983). Biochim. Biophys. Acta, 742, 558–564. [DOI] [PubMed]
- Machius, M., Declerck, N., Huber, R. & Wiegand, G. (1998). Structure, 6, 281–292. [DOI] [PubMed]
- Masys, D. R., Bajaj, S. P. & Rapaport, S. I. (1982). Blood, 60, 1143–1150. [PubMed]
- Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). Acta Cryst. D67, 355–367. [DOI] [PMC free article] [PubMed]
- Navaza, J. (1994). Acta Cryst. A50, 157–163.
- Neuenschwander, P. F., Fiore, M. M. & Morrissey, J. H. (1993). J. Biol. Chem. 268, 21489–21492. [PubMed]
- Neuenschwander, P. F. & Morrissey, J. H. (1992). J. Biol. Chem. 267, 14477–14482. [PubMed]
- Nonaka, T., Fujihashi, M., Kita, A., Hagihara, H., Ozaki, K., Ito, S. & Miki, K. (2003). J. Biol. Chem. 278, 24818–24824. [DOI] [PubMed]
- Orthner, C. L. & Kosow, D. P. (1978). Arch. Biochem. Biophys. 185, 400–406. [DOI] [PubMed]
- Orthner, C. L. & Kosow, D. P. (1980). Arch. Biochem. Biophys. 202, 63–75. [DOI] [PubMed]
- Otwinowski, Z. & Minor, W. (1997). Methods Enzymol. 276, 307–326. [DOI] [PubMed]
- Padmanabhan, K., Padmanabhan, K. P., Tulinsky, A., Park, C. H., Bode, W., Huber, R., Blankenship, D. T., Cardin, A. D. & Kisiel, W. (1993). J. Mol. Biol. 232, 947–966. [DOI] [PubMed]
- Petrovan, R. J. & Ruf, W. (2000). Biochemistry, 39, 14457–14463. [DOI] [PubMed]
- Price, P. A., Otsuka, A. A., Poser, J. W., Kristaponis, J. & Raman, N. (1976). Proc. Natl Acad. Sci. USA, 73, 1447–1451. [DOI] [PMC free article] [PubMed]
- Radcliffe, R. & Nemerson, Y. (1976). J. Biol. Chem. 251, 4749–4802. [PubMed]
- Rezaie, A. R. & He, X. (2000). Biochemistry, 39, 1817–1825. [DOI] [PubMed]
- Ruf, W., Rehemtulla, A., Morrissey, J. H. & Edgington, T. S. (1991). J. Biol. Chem. 266, 2158–2166. [PubMed]
- Schmidt, A. E., Padmanabhan, K., Underwood, M. C., Bode, W., Mather, T. & Bajaj, S. P. (2002). J. Biol. Chem. 277, 28987–28995. [DOI] [PubMed]
- Schmidt, A. E., Stewart, J. E., Mathur, A., Krishnaswamy, S. & Bajaj, S. P. (2005). J. Mol. Biol. 350, 78–91. [DOI] [PubMed]
- Segal, I. H. (1975). Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme Systems. New York: John Wiley & Sons.
- Shannon, R. D. (1976). Acta Cryst. A32, 751–767.
- Soriano-Garcia, M., Padmanabhan, K., De Vos, A. M. & Tulinsky, A. (1992). Biochemistry, 31, 2554–2566. [DOI] [PubMed]
- Sichler, K., Banner, D. W., D’Arcy, A., Hopfner, K. P., Huber, R., Bode, W., Kresse, G. B., Kopetzki, E. & Brandstetter, H. (2002). J. Mol. Biol. 322, 591–603. [DOI] [PubMed]
- Steiner, S. A. & Castellino, F. J. (1985). Biochemistry, 24, 609–617. [DOI] [PubMed]
- Straume, M. & Johnson, M. L. (1992). Methods Enzymol. 210, 87–105. [DOI] [PubMed]
- Stubbs, M. T. & Bode, W. (1993). Thromb. Res. 69, 1–58. [DOI] [PubMed]
- Underwood, M. C., Zhong, D., Mathur, A., Heyduk, T. & Bajaj, S. P. (2000). J. Biol. Chem. 275, 36876–36884. [DOI] [PubMed]
- Vadivel, K., Agah, S., Messer, A. S., Cascio, D., Bajaj, M. S., Krishnaswamy, S., Esmon, C. T., Padmanabhan, K. & Bajaj, S. P. (2013). J. Mol. Biol. 425, 1961–1981. [DOI] [PMC free article] [PubMed]
- Vadivel, K., Schreuder, H. A., Liesum, A., Schmidt, A. E., Goldsmith, G. & Bajaj, S. P. (2019). J. Thromb. Haemost. 17, 574–584. [DOI] [PMC free article] [PubMed]
- Waxman, E., Ross, J. B. A., Laue, T. M., Guha, A., Thiruvikraman, S. V., Lin, T. C., Konigsberg, W. H. & Nemerson, Y. (1992). Biochemistry, 31, 3998–4003. [DOI] [PubMed]
- Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., McNicholas, S. J., Murshudov, G. N., Pannu, N. S., Potterton, E. A., Powell, H. R., Read, R. J., Vagin, A. & Wilson, K. S. (2011). Acta Cryst. D67, 235–242. [DOI] [PMC free article] [PubMed]
- Yamamoto, M., Nakagaki, T. & Kisiel, W. (1992). J. Biol. Chem. 267, 19089–19094. [PubMed]
- Zhang, E. & Tulinsky, A. (1997). Biophys. Chem. 63, 185–200. [DOI] [PubMed]
- Zhong, D., Bajaj, M. S., Schmidt, A. E. & Bajaj, S. P. (2002). J. Biol. Chem. 277, 3622–3631. [DOI] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
PDB reference: factor VIIa–soluble tissue factor complex, 4ibl